Parallel Advisors LLC Buys 12,138 Shares of Novo Nordisk A/S $NVO

Parallel Advisors LLC raised its stake in Novo Nordisk A/S (NYSE:NVO) by 27.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,856 shares of the company’s stock after acquiring an additional 12,138 shares during the quarter. Parallel Advisors LLC’s holdings in Novo Nordisk A/S were worth $2,053,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Quotient Wealth Partners LLC grew its stake in shares of Novo Nordisk A/S by 2.0% during the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after purchasing an additional 177 shares during the last quarter. Certuity LLC increased its holdings in shares of Novo Nordisk A/S by 3.6% in the fourth quarter. Certuity LLC now owns 5,052 shares of the company’s stock valued at $257,000 after purchasing an additional 177 shares in the last quarter. Oakworth Capital Inc. raised its position in Novo Nordisk A/S by 41.6% in the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock worth $31,000 after purchasing an additional 182 shares during the last quarter. True North Advisors LLC lifted its holdings in Novo Nordisk A/S by 3.9% during the 4th quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock worth $270,000 after buying an additional 199 shares in the last quarter. Finally, Asio Capital LLC lifted its holdings in Novo Nordisk A/S by 3.9% during the 4th quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock worth $274,000 after buying an additional 200 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk received a boost from continued momentum behind Wegovy, including reports that the newly approved oral version in Europe could expand the drug’s reach and improve the company’s competitive position. Wegovy Pill in Europe – Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug
• Positive Sentiment: Citi reportedly raised its price target on Novo Nordisk ahead of earnings, citing stronger-than-expected Wegovy pill launch trends and higher sales and profit estimates, which supports a more bullish near-term outlook. Citi lifts Novo Nordisk target on strong GLP-1 pill launch
• Positive Sentiment: Novo Nordisk also announced progress in China through Fangzhou’s launch of Kyinsu, a once-weekly basal insulin/GLP-1 combination therapy, broadening its international diabetes footprint. Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China
• Neutral Sentiment: The company said it is continuing a DKK 15 billion share repurchase program, which can help offset dilution and signal management confidence, but is not a major new catalyst on its own. Novo Nordisk A/S – share repurchase programme
• Negative Sentiment: The biggest near-term headwind is Novo Nordisk’s lawsuit against Eli Lilly, alleging misleading advertising and outdated clinical data in campaigns for Zepbound and Mounjaro. While the suit aims to protect Novo’s brands, it also highlights intensifying competition in obesity drugs and adds litigation risk. Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $49.40 on Wednesday. The firm’s 50 day moving average price is $46.21 and its two-hundred day moving average price is $45.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $71.79. The stock has a market cap of $220.58 billion, a PE ratio of 11.60, a PEG ratio of 4.53 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. As a group, analysts forecast that Novo Nordisk A/S will post 3.38 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the company. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday. Wolfe Research began coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. Finally, Zacks Research cut Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Five investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.